Illumina, Inc. $ILMN Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 3.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 886,865 shares of the life sciences company’s stock after selling 30,381 shares during the quarter. Illumina comprises about 1.3% of Amova Asset Management Americas Inc.’s holdings, making the stock its 21st largest position. Amova Asset Management Americas Inc.’s holdings in Illumina were worth $116,241,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Empowered Funds LLC boosted its position in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after acquiring an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Illumina in the second quarter worth approximately $621,000. CW Advisors LLC acquired a new stake in shares of Illumina in the second quarter worth approximately $275,000. Marshall Wace LLP boosted its position in shares of Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC boosted its position in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is owned by insiders.

Illumina Stock Up 1.3%

NASDAQ ILMN opened at $160.03 on Wednesday. The stock has a market cap of $24.21 billion, a PE ratio of 29.10, a P/E/G ratio of 2.96 and a beta of 1.50. Illumina, Inc. has a fifty-two week low of $85.00 and a fifty-two week high of $177.22. The business has a 50 day moving average price of $139.27 and a two-hundred day moving average price of $134.20. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the company posted $0.97 EPS. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Finally, Royal Bank Of Canada assumed coverage on shares of Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price for the company. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $138.38.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.